{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:52:20Z","timestamp":1791247940241,"version":"4.1.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prader\u2013Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder characterised by hypothalamic dysfunction and profound dysregulation in hunger and appetite regulation, endocrine function, metabolism and behaviour. Hyperphagia is a defining clinical feature and a major contributor to morbidity, mortality and caregiver burden. Increasing evidence suggests that hyperphagia in PWS represents a multidimensional disorder rather than excessive appetite alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In December 2024, an international meeting of clinical and scientific experts was convened in Toulouse, France, to explore current understanding of hyperphagia in PWS, challenges in assessment, and evolving approaches to management across the lifespan. Although not a formal consensus process, several consistent themes emerged. These included limitations of existing assessment tools, the need for multidimensional evaluation (including use of instruments such as the Hyperphagia Questionnaire and Hyperphagia Questionnaire for Clinical Trials (HQ-CT). The central role of structured food environments, and vulnerabilities during transition to adult care were also identified as key themes. Experts emphasised that hyperphagia reflects interactions between impaired satiety signalling, activation in reward neurocircuitry, autonomic dysfunction and environmental factors. Management therefore requires integrated biological, behavioural and environmental approaches. While food security and structured support remain foundational, emerging pharmacological therapies may complement multidisciplinary care and reduce caregiver burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Hyperphagia in PWS should be conceptualised as a complex, multidimensional disorder requiring comprehensive assessment and integrated management. Future priorities include development of additional validated outcome measures, identification of biomarkers, and care models that better align mechanistic insights with real-world clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04601-1","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:02:22Z","timestamp":1791201742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hyperphagia in Prader\u2013Willi syndrome: linking hypothalamic dysfunction to clinical assessment and management across the lifespan"],"prefix":"10.1186","volume":"21","author":[{"given":"Maith\u00e9","family":"Tauber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00eblle","family":"Diene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Poitou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"H\u00f6ybye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien F.","family":"Gevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P.","family":"Goldstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Haqq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Hi","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley H.","family":"Shoemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice L.","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"de Graaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Manzardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assumpta","family":"Caix\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena G.","family":"Bochukova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dairine","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"4","key":"4601_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/1573396315666190716120925","volume":"15","author":"MG Butler","year":"2019","unstructured":"Butler MG, Miller JL, Forster JL. Prader-Willi Syndrome - clinical genetics, diagnosis and treatment approaches: An update. Curr Pediatr Rev. 2019;15(4):207\u201344. https:\/\/doi.org\/10.2174\/1573396315666190716120925.","journal-title":"Curr Pediatr Rev"},{"key":"4601_CR2","doi-asserted-by":"publisher","unstructured":"Butler MG. Prader-Willi syndrome and chromosome 15q11.2 BP1-BP2 region: a review. Int J Mol Sci. 2023;21(5). https:\/\/doi.org\/10.3390\/ijms24054271.","DOI":"10.3390\/ijms24054271"},{"issue":"4","key":"4601_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/s2213-8587(21)00002-4","volume":"9","author":"M Tauber","year":"2021","unstructured":"Tauber M, Hoybye C. Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction. Lancet Diabetes Endocrinol Apr. 2021;9(4):235\u201346. https:\/\/doi.org\/10.1016\/s2213-8587(21)00002-4.","journal-title":"Lancet Diabetes Endocrinol Apr"},{"issue":"3","key":"4601_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10286-022-00909-7","volume":"33","author":"MG Butler","year":"2023","unstructured":"Butler MG, Victor AK, Reiter LT. Autonomic nervous system dysfunction in Prader-Willi syndrome. Clin Auton Res Jun. 2023;33(3):281\u20136. https:\/\/doi.org\/10.1007\/s10286-022-00909-7.","journal-title":"Clin Auton Res Jun"},{"issue":"1","key":"4601_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s11689-021-09373-2","volume":"21","author":"L Schwartz","year":"2021","unstructured":"Schwartz L, Caix\u00e0s A, Dimitropoulos A, et al. Behavioral features in Prader-Willi syndrome (PWS): consensus paper from the International PWS Clinical Trial Consortium. J Neurodev Disord Jun. 2021;21(1):25. https:\/\/doi.org\/10.1186\/s11689-021-09373-2.","journal-title":"J Neurodev Disord Jun"},{"issue":"1","key":"4601_CR6","doi-asserted-by":"publisher","first-page":"20573","DOI":"10.1038\/s41598-023-48024-5","volume":"23","author":"L Matesevac","year":"2023","unstructured":"Matesevac L, Vrana-Diaz CJ, Bohonowych JE, Schwartz L, Strong TV. Analysis of Hyperphagia Questionnaire for Clinical Trials (HQ-CT) scores in typically developing individuals and those with Prader-Willi syndrome. Sci Rep Nov. 2023;23(1):20573. https:\/\/doi.org\/10.1038\/s41598-023-48024-5.","journal-title":"Sci Rep Nov"},{"key":"4601_CR7","doi-asserted-by":"publisher","unstructured":"Rozensztrauch A, \u015amigiel R. Quality of life in children with Prader-Willi syndrome and the impact of the disease on the functioning of families. Int J Environ Res Public Health. 2022;6(23). https:\/\/doi.org\/10.3390\/ijerph192316330.","DOI":"10.3390\/ijerph192316330"},{"issue":"7","key":"4601_CR8","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.clinthera.2021.05.013","volume":"43","author":"TA Lavelle","year":"2021","unstructured":"Lavelle TA, Crossnohere NL, Bridges JFP. Quantifying the burden of hyperphagia in Prader-Willi syndrome using quality-adjusted life-years. Clin Ther Jul. 2021;43(7):1164\u2013e11784. https:\/\/doi.org\/10.1016\/j.clinthera.2021.05.013.","journal-title":"Clin Ther Jul"},{"issue":"1","key":"4601_CR9","doi-asserted-by":"publisher","first-page":"104379","DOI":"10.1016\/j.ejmg.2021.104379","volume":"65","author":"SA Bellis","year":"2022","unstructured":"Bellis SA, Kuhn I, Adams S, Mullarkey L, Holland A. The consequences of hyperphagia in people with Prader-Willi Syndrome: a systematic review of studies of morbidity and mortality. Eur J Med Genet Jan. 2022;65(1):104379. https:\/\/doi.org\/10.1016\/j.ejmg.2021.104379.","journal-title":"Eur J Med Genet Jan"},{"issue":"12","key":"4601_CR10","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1111\/dom.13021","volume":"19","author":"SE McCandless","year":"2017","unstructured":"McCandless SE, Yanovski JA, Miller J, et al. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab Dec. 2017;19(12):1751\u201361. https:\/\/doi.org\/10.1111\/dom.13021.","journal-title":"Diabetes Obes Metab Dec"},{"issue":"5","key":"4601_CR11","doi-asserted-by":"publisher","first-page":"fcac229","DOI":"10.1093\/braincomms\/fcac229","volume":"4","author":"SSG Brown","year":"2022","unstructured":"Brown SSG, Manning KE, Fletcher P, Holland A. In vivo neuroimaging evidence of hypothalamic alteration in Prader-Willi syndrome. Brain Commun. 2022;4(5):fcac229. https:\/\/doi.org\/10.1093\/braincomms\/fcac229.","journal-title":"Brain Commun"},{"key":"4601_CR12","doi-asserted-by":"publisher","first-page":"103952","DOI":"10.1016\/j.ebiom.2022.103952","volume":"78","author":"A Holland","year":"2022","unstructured":"Holland A, Manning K, Whittington J. The paradox of Prader-Willi syndrome revisited: Making sense of the phenotype. EBioMedicine Apr. 2022;78:103952. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103952.","journal-title":"EBioMedicine Apr"},{"issue":"5","key":"4601_CR13","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/ijo.2011.204","volume":"36","author":"LM Holsen","year":"2012","unstructured":"Holsen LM, Savage CR, Martin LE, et al. Importance of reward and prefrontal circuitry in hunger and satiety: Prader-Willi syndrome vs simple obesity. Int J Obes (Lond) May. 2012;36(5):638\u201347. https:\/\/doi.org\/10.1038\/ijo.2011.204.","journal-title":"Int J Obes (Lond) May"},{"issue":"3","key":"4601_CR14","doi-asserted-by":"publisher","first-page":"fcad138","DOI":"10.1093\/braincomms\/fcad138","volume":"5","author":"K Strelnikov","year":"2023","unstructured":"Strelnikov K, Debladis J, Salles J, et al. Amygdala hyperactivation relates to eating behaviour: a potential indicator of food addiction in Prader-Willi syndrome. Brain Commun. 2023;5(3):fcad138. https:\/\/doi.org\/10.1093\/braincomms\/fcad138.","journal-title":"Brain Commun"},{"issue":"7","key":"4601_CR15","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1210\/clinem\/dgad015","volume":"16","author":"E Roof","year":"2023","unstructured":"Roof E, Deal CL, McCandless SE, et al. Intranasal carbetocin reduces hyperphagia, anxiousness, and distress in Prader-Willi Syndrome: CARE-PWS Phase 3 trial. J Clin Endocrinol Metab 2023;108(7):1696\u2013708. https:\/\/doi.org\/10.1210\/clinem\/dgad015","journal-title":"J Clin Endocrinol Metab Jun"},{"issue":"6505","key":"4601_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/372425a0","volume":"1","author":"Y Zhang","year":"1994","unstructured":"Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature Dec. 1994;1(6505):425\u201332. https:\/\/doi.org\/10.1038\/372425a0.","journal-title":"Nature Dec"},{"issue":"3","key":"4601_CR17","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1038\/emm.2016.4","volume":"11","author":"E Roh","year":"2016","unstructured":"Roh E, Song DK, Kim MS. Emerging role of the brain in the homeostatic regulation of energy and glucose metabolism. Exp Mol Med Mar. 2016;11(3):e216. https:\/\/doi.org\/10.1038\/emm.2016.4.","journal-title":"Exp Mol Med Mar"},{"key":"4601_CR18","unstructured":"Hosseini SS, Brown SSG, Holland A. January. Altered hypothalamic functional connectivity in adults with PWS. In: Foundation for PWS Research Symposium; 2024 Sep 25-26; Atlanta, GA. [Internet]. 2024 [cited 2026 Sep 11]. Available from: https:\/\/www.fpwr.org\/hubfs\/2024%20PWS%20Research%20Symposium%20Abstract%20Booklet.pdf?hsCtaTracking=c1c7099e-c7f0-4d7b-a99e-a99959524800%7C4a8e8ea2-cc35-40aa-bbe6-67469da98c1b."},{"issue":"7","key":"4601_CR19","doi-asserted-by":"publisher","first-page":"e12994","DOI":"10.1111\/jne.12994","volume":"33","author":"F Correa-da-Silva","year":"2021","unstructured":"Correa-da-Silva F, Fliers E, Swaab DF, Yi CX. Hypothalamic neuropeptides and neurocircuitries in Prader Willi syndrome. J Neuroendocrinol Jul. 2021;33(7):e12994. https:\/\/doi.org\/10.1111\/jne.12994.","journal-title":"J Neuroendocrinol Jul"},{"issue":"9","key":"4601_CR20","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1210\/jcem.86.9.7814","volume":"86","author":"AP Goldstone","year":"2001","unstructured":"Goldstone AP, Thomas EL, Brynes AE, et al. Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution. J Clin Endocrinol Metab Sep. 2001;86(9):4330\u20138. https:\/\/doi.org\/10.1210\/jcem.86.9.7814","journal-title":"J Clin Endocrinol Metab Sep"},{"issue":"6","key":"4601_CR21","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1365-2265.2007.02991.x","volume":"67","author":"AM Haqq","year":"2007","unstructured":"Haqq AM, Muehlbauer M, Svetkey LP, et al. Altered distribution of adiponectin isoforms in children with Prader-Willi syndrome (PWS): association with insulin sensitivity and circulating satiety peptide hormones. Clin Endocrinol (Oxf) Dec. 2007;67(6):944\u201351. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02991.x.","journal-title":"Clin Endocrinol (Oxf) Dec"},{"issue":"1","key":"4601_CR22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1210\/jc.2002-021052","volume":"88","author":"AM Haqq","year":"2003","unstructured":"Haqq AM, Farooqi IS, O\u2019Rahilly S, et al. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab Jan. 2003;88(1):174\u20138. https:\/\/doi.org\/10.1210\/jc.2002-021052.","journal-title":"J Clin Endocrinol Metab Jan"},{"issue":"6","key":"4601_CR23","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1365-2265.2008.03385.x","volume":"69","author":"AM Haqq","year":"2008","unstructured":"Haqq AM, Grambow SC, Muehlbauer M, et al. Ghrelin concentrations in Prader-Willi syndrome (PWS) infants and children: changes during development. Clin Endocrinol (Oxf) Dec. 2008;69(6):911\u201320. https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03385.x.","journal-title":"Clin Endocrinol (Oxf) Dec"},{"issue":"5","key":"4601_CR24","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1210\/jc.2003-032209","volume":"90","author":"AP Goldstone","year":"2005","unstructured":"Goldstone AP, Patterson M, Kalingag N, et al. Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J Clin Endocrinol Metab May. 2005;90(5):2681\u201390. https:\/\/doi.org\/10.1210\/jc.2003-032209.","journal-title":"J Clin Endocrinol Metab May"},{"issue":"1","key":"4601_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1172\/JCI88648","volume":"3","author":"LC Burnett","year":"2017","unstructured":"Burnett LC, LeDuc CA, Sulsona CR, et al. Deficiency in prohormone convertase PC1 impairs prohormone processing in Prader-Willi syndrome. J Clin Invest Jan. 2017;127(1):293\u2013305. https:\/\/doi.org\/10.1172\/JCI88648.","journal-title":"J Clin Invest Jan"},{"issue":"2","key":"4601_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/jc.2015-2665","volume":"101","author":"AP Goldstone","year":"2016","unstructured":"Goldstone AP, Miras AD, Scholtz S, et al. Link Between Increased Satiety Gut Hormones and Reduced Food Reward After Gastric Bypass Surgery for Obesity. J Clin Endocrinol Metab Feb. 2016;101(2):599\u2013609. https:\/\/doi.org\/10.1210\/jc.2015-2665.","journal-title":"J Clin Endocrinol Metab Feb"},{"key":"4601_CR27","doi-asserted-by":"publisher","unstructured":"Diene G, Benvegnu G, Brochado C, et al. Circulating levels of ghrelin and hyperphagia in patients with rare genetic neurodevelopmental disorders. J Clin Endocrinol Metab. 2026;111(8):2220\u201331. https:\/\/doi.org\/10.1210\/clinem\/dgag081.","DOI":"10.1210\/clinem\/dgag081"},{"issue":"1","key":"4601_CR28","doi-asserted-by":"publisher","first-page":"E225","DOI":"10.1210\/jc.2010-1733","volume":"96","author":"AM Haqq","year":"2011","unstructured":"Haqq AM, Muehlbauer MJ, Newgard CB, Grambow S, Freemark M. The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body mass index. J Clin Endocrinol Metab Jan. 2011;96(1):E225\u201332. https:\/\/doi.org\/10.1210\/jc.2010-1733.","journal-title":"J Clin Endocrinol Metab Jan"},{"key":"4601_CR29","doi-asserted-by":"publisher","unstructured":"Bueno M, Boixadera-Planas E, Blanco-Hinojo L, et al. Hunger and satiety peptides: is there a pattern to classify patients with Prader-Willi syndrome? J Clin Med. 2021;4(21). https:\/\/doi.org\/10.3390\/jcm10215170.","DOI":"10.3390\/jcm10215170"},{"key":"4601_CR30","doi-asserted-by":"publisher","unstructured":"Hinton EC, Holland AJ, Owen AM. Functional neuroimaging in Prader\u2013Willi syndrome. Int J Obes. 2007;31(2):390\u2013391. https:\/\/doi.org\/10.1038\/sj.ijo.0803412.","DOI":"10.1038\/sj.ijo.0803412"},{"issue":"1","key":"4601_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41380-020-00917-x","volume":"26","author":"J Salles","year":"2021","unstructured":"Salles J, Lacassagne E, Eddiry S, Franchitto N, Salles JP, Tauber M. What can we learn from PWS and SNORD116 genes about the pathophysiology of addictive disorders? Mol Psychiatry Jan. 2021;26(1):51\u20139. https:\/\/doi.org\/10.1038\/s41380-020-00917-x.","journal-title":"Mol Psychiatry Jan"},{"issue":"4","key":"4601_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.6065\/apem.2142164.082","volume":"26","author":"SJ Kim","year":"2021","unstructured":"Kim SJ, Cho SY, Jin DK. Prader-Willi syndrome: an update on obesity and endocrine problems. Ann Pediatr Endocrinol Metab Dec. 2021;26(4):227\u201336. https:\/\/doi.org\/10.6065\/apem.2142164.082.","journal-title":"Ann Pediatr Endocrinol Metab Dec"},{"issue":"5","key":"4601_CR33","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/ajmg.a.33951","volume":"155A","author":"JL Miller","year":"2011","unstructured":"Miller JL, Lynn CH, Driscoll DC, et al. Nutritional phases in Prader-Willi syndrome. Am J Med Genet A May. 2011;155A(5):1040\u20139. https:\/\/doi.org\/10.1002\/ajmg.a.33951.","journal-title":"Am J Med Genet A May"},{"issue":"3","key":"4601_CR34","doi-asserted-by":"publisher","first-page":"e0248739","DOI":"10.1371\/journal.pone.0248739","volume":"16","author":"N Kayadjanian","year":"2021","unstructured":"Kayadjanian N, Vrana-Diaz C, Bohonowych J, et al. Characteristics and relationship between hyperphagia, anxiety, behavioral challenges and caregiver burden in Prader-Willi syndrome. PLoS ONE. 2021;16(3):e0248739. https:\/\/doi.org\/10.1371\/journal.pone.0248739.","journal-title":"PLoS ONE"},{"issue":"3","key":"4601_CR35","doi-asserted-by":"publisher","first-page":"e0194655","DOI":"10.1371\/journal.pone.0194655","volume":"13","author":"N Kayadjanian","year":"2018","unstructured":"Kayadjanian N, Schwartz L, Farrar E, Comtois KA, Strong TV. High levels of caregiver burden in Prader-Willi syndrome. PLoS ONE. 2018;13(3):e0194655. https:\/\/doi.org\/10.1371\/journal.pone.0194655.","journal-title":"PLoS ONE"},{"key":"4601_CR36","doi-asserted-by":"publisher","first-page":"1382583","DOI":"10.3389\/fendo.2024.1382583","volume":"15","author":"SF Madeo","year":"2024","unstructured":"Madeo SF, Zagaroli L, Vandelli S, et al. Endocrine features of Prader-Willi syndrome: a narrative review focusing on genotype-phenotype correlation. Front Endocrinol (Lausanne). 2024;15:1382583. https:\/\/doi.org\/10.3389\/fendo.2024.1382583.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"4601_CR37","doi-asserted-by":"publisher","first-page":"e72640","DOI":"10.1371\/journal.pone.0072640","volume":"8","author":"L Yang","year":"2013","unstructured":"Yang L, Zhan GD, Ding JJ, et al. Psychiatric illness and intellectual disability in the Prader-Willi syndrome with different molecular defects\u2013a meta analysis. PLoS ONE. 2013;8(8):e72640. https:\/\/doi.org\/10.1371\/journal.pone.0072640.","journal-title":"PLoS ONE"},{"issue":"1","key":"4601_CR38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13052-022-01319-1","volume":"23","author":"L Zhang","year":"2022","unstructured":"Zhang L, Liu X, Zhao Y, et al. Genetic subtypes and phenotypic characteristics of 110 patients with Prader-Willi syndrome. Ital J Pediatr Jul. 2022;23(1):121. https:\/\/doi.org\/10.1186\/s13052-022-01319-1.","journal-title":"Ital J Pediatr Jul"},{"issue":"1","key":"4601_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ando.2021.12.003","volume":"83","author":"B Dubern","year":"2022","unstructured":"Dubern B, Mosbah H, Pigeyre M, Cl\u00e9ment K, Poitou C. Rare genetic causes of obesity: Diagnosis and management in clinical care. Ann Endocrinol (Paris) Feb. 2022;83(1):63\u201372. https:\/\/doi.org\/10.1016\/j.ando.2021.12.003.","journal-title":"Ann Endocrinol (Paris) Feb"},{"issue":"11","key":"4601_CR40","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1007\/s00431-023-05159-x","volume":"182","author":"F Mainieri","year":"2023","unstructured":"Mainieri F, La Bella S, Rinaldi M, Chiarelli F. Rare genetic forms of obesity in childhood and adolescence, a comprehensive review of their molecular mechanisms and diagnostic approach. Eur J Pediatr Nov. 2023;182(11):4781\u201393. https:\/\/doi.org\/10.1007\/s00431-023-05159-x.","journal-title":"Eur J Pediatr Nov"},{"issue":"2","key":"4601_CR41","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s13679-023-00543-y","volume":"13","author":"LML Carvalho","year":"2024","unstructured":"Carvalho LML, Jorge AAL, Bertola DR, Krepischi ACV, Rosenberg C. A comprehensive review of syndromic forms of obesity: Genetic etiology, clinical features and molecular diagnosis. Curr Obes Rep Jun. 2024;13(2):313\u201337. https:\/\/doi.org\/10.1007\/s13679-023-00543-y.","journal-title":"Curr Obes Rep Jun"},{"key":"4601_CR42","doi-asserted-by":"publisher","first-page":"106161","DOI":"10.1016\/j.appet.2022.106161","volume":"178","author":"S Zorn","year":"2022","unstructured":"Zorn S, von Schnurbein J, Schirmer M, Brandt S, Wabitsch M. Measuring hyperphagia in patients with monogenic and syndromic obesity. Appetite Nov 1. 2022;178:106161. https:\/\/doi.org\/10.1016\/j.appet.2022.106161.","journal-title":"Appetite Nov 1"},{"issue":"2","key":"4601_CR43","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000548535","volume":"19","author":"E Guillon","year":"2026","unstructured":"Guillon E, Dubern B, Clement K, Poitou C. Multidimensional Characterisation of Eating Behaviour in Genetic Obesity: A Systematic Review. Obes Facts. 2026;19(2):164\u201392. https:\/\/doi.org\/10.1159\/000548535.","journal-title":"Obes Facts"},{"issue":"7","key":"4601_CR44","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/oby.2007.216","volume":"15","author":"EM Dykens","year":"2007","unstructured":"Dykens EM, Maxwell MA, Pantino E, Kossler R, Roof E. Assessment of hyperphagia in Prader-Willi syndrome. Obesity (Silver Spring) Jul. 2007;15(7):1816\u201326. https:\/\/doi.org\/10.1038\/oby.2007.216.","journal-title":"Obesity (Silver Spring) Jul"},{"issue":"3","key":"4601_CR45","doi-asserted-by":"publisher","first-page":"A25","DOI":"10.1016\/j.jval.2015.03.154","volume":"18","author":"SE Fehnel","year":"2015","unstructured":"Fehnel SE, Brown TM, Nelson L, et al. Development of the Hyperphagia Questionnaire for use in Prader-Willi syndrome clinical trials. Value Health. 2015;18(3):A25. https:\/\/doi.org\/10.1016\/j.jval.2015.03.154.","journal-title":"Value Health"},{"key":"4601_CR46","doi-asserted-by":"publisher","first-page":"e2022014","DOI":"10.4178\/epih.e2022014","volume":"44","author":"SY Cho","year":"2022","unstructured":"Cho SY, Kang D, Im M, et al. Development and validation of the Pediatric-Youth Hyperphagia Assessment for Prader-Willi syndrome. Epidemiol Health. 2022;44:e2022014. https:\/\/doi.org\/10.4178\/epih.e2022014.","journal-title":"Epidemiol Health"},{"issue":"2","key":"4601_CR47","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jval.2022.08.004","volume":"26","author":"SP Cotter","year":"2023","unstructured":"Cotter SP, Schwartz L, Strong TV, Bender RH, Fehnel SE. The Prader-Willi Syndrome Anxiousness and Distress Behaviors Questionnaire: Development and psychometric validation. Value Health Feb. 2023;26(2):243\u201350. https:\/\/doi.org\/10.1016\/j.jval.2022.08.004.","journal-title":"Value Health Feb"},{"issue":"7","key":"4601_CR48","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The Clinical Global Impressions Scale: Applying a research tool in clinical practice. Psychiatry (Edgmont) Jul. 2007;4(7):28\u201337.","journal-title":"Psychiatry (Edgmont) Jul"},{"issue":"1","key":"4601_CR49","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s11689-024-09589-y","volume":"8","author":"EM Dykens","year":"2025","unstructured":"Dykens EM, Roof E, Hunt-Hawkins H, Strong TV. Validation of the Food Safe Zone questionnaire for families of individuals with Prader-Willi syndrome. J Neurodev Disord Feb. 2025;8(1):6. https:\/\/doi.org\/10.1186\/s11689-024-09589-y.","journal-title":"J Neurodev Disord Feb"},{"key":"4601_CR50","doi-asserted-by":"publisher","first-page":"112429","DOI":"10.1016\/j.ijpsycho.2024.112429","volume":"205","author":"LJ Rice","year":"2024","unstructured":"Rice LJ, Agu J, Carter CS, et al. The relationship between cardiac activity, behaviour and endogenous oxytocin and vasopressin in Prader-Willi Syndrome: An exploratory study. Int J Psychophysiol Nov. 2024;205:112429. https:\/\/doi.org\/10.1016\/j.ijpsycho.2024.112429.","journal-title":"Int J Psychophysiol Nov"},{"issue":"2","key":"4601_CR51","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/87565641.2017.1367395","volume":"43","author":"AP Key","year":"2018","unstructured":"Key AP, Dykens EM. Eye tracking as a marker of hyperphagia in Prader-Willi syndrome. Dev Neuropsychol. 2018;43(2):152\u201361. https:\/\/doi.org\/10.1080\/87565641.2017.1367395.","journal-title":"Dev Neuropsychol"},{"issue":"7","key":"4601_CR52","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1002\/ajmg.a.61606","volume":"182","author":"AP Key","year":"2020","unstructured":"Key AP, Zengin-Bolatkale H, Dimitropoulos A, Doernberg E. Eye tracking as an objective measure of hyperphagia in children with Prader-Willi syndrome. Am J Med Genet A Jul. 2020;182(7):1655\u201363. https:\/\/doi.org\/10.1002\/ajmg.a.61606.","journal-title":"Am J Med Genet A Jul"},{"key":"4601_CR53","doi-asserted-by":"publisher","unstructured":"Poitou C, Holland A, Hoybye C, et al. The transition from pediatric to adult care in individuals with Prader-Willi syndrome. Endocr Connect. 2023;1(1). https:\/\/doi.org\/10.1530\/EC-22-0373.","DOI":"10.1530\/EC-22-0373"},{"key":"4601_CR54","unstructured":"Driscoll DJ, Miller JL, Cassidy SB. Prader-Willi Syndrome. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, eds. GeneReviews((R)); 1993."},{"issue":"12","key":"4601_CR55","doi-asserted-by":"publisher","first-page":"e4671","DOI":"10.1210\/clinem\/dgaa621","volume":"1","author":"K Pellikaan","year":"2020","unstructured":"Pellikaan K, Rosenberg AGW, Kattentidt-Mouravieva AA, et al. Missed diagnoses and health problems in adults with Prader-Willi Syndrome: Recommendations for screening and treatment. J Clin Endocrinol Metab Dec. 2020;105(12):e4671\u201387. https:\/\/doi.org\/10.1210\/clinem\/dgaa621.","journal-title":"J Clin Endocrinol Metab Dec"},{"issue":"1","key":"4601_CR56","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13023-024-03035-x","volume":"7","author":"BM Hughes","year":"2024","unstructured":"Hughes BM, Holland A, H\u00f6debeck-Stuntebeck N, et al. Body weight, behaviours of concern, and social contact in adults and adolescents with Prader-Willi syndrome in full-time care services: Findings from pooled international archival data. Orphanet J Rare Dis Feb. 2024;7(1):48. https:\/\/doi.org\/10.1186\/s13023-024-03035-x.","journal-title":"Orphanet J Rare Dis Feb"},{"issue":"9","key":"4601_CR57","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/ajmg.a.34171","volume":"155A","author":"M Sinnema","year":"2011","unstructured":"Sinnema M, Maaskant MA, van Lantman-de Valk S. Physical health problems in adults with Prader-Willi syndrome. Am J Med Genet A Sep. 2011;155A(9):2112\u201324. https:\/\/doi.org\/10.1002\/ajmg.a.34171.","journal-title":"Am J Med Genet A Sep"},{"key":"4601_CR58","doi-asserted-by":"publisher","unstructured":"Allas S, Caixas A, Poitou C, et al. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial. PLoS One. 2018;13(1):e0190849. https:\/\/doi.org\/10.1371\/journal.pone.0190849.","DOI":"10.1371\/journal.pone.0190849"},{"key":"4601_CR59","unstructured":"Millendo Therapeutics. Millendo therapeutics announces topline results for pivotal phase 2b study of Livoletide in patients with Prader-Willi syndrome (PWS). Available from: https:\/\/www.sec.gov\/Archives\/edgar\/data\/1544227\/000110465920043387\/tm2015079d1_ex99-1.htm."},{"key":"4601_CR60","doi-asserted-by":"publisher","unstructured":"McCandless SE, Yanovski JA, Miller J, Fu C, Bird LM, Salehi P, et al. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2017 Dec;19(12):1751\u201361. https:\/\/doi.org\/10.1111\/dom.13021.","DOI":"10.1111\/dom.13021"},{"key":"4601_CR61","doi-asserted-by":"publisher","unstructured":"Roof E, Strong TV, Stafford DEJ, Singh D, Roy SM, Doshi D, Zhang Y, Salvucci A, Youakim JM, McCandless SE; COMPASS PWS Investigators. Carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome: results from the randomized, placebo-controlled, phase 3 compass PWS Study. Clin Ther. 2026;S0149-2918(26)00234\u20131. Epub ahead of print. https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.019.","DOI":"10.1016\/j.clinthera.2026.06.019"},{"key":"4601_CR62","unstructured":"Acadia Pharmaceuticals. Acadia Pharmaceuticals announces Phase 3 COMPASS PWS trial of intranasal carbetocin (ACP-101) for hyperphagia in Prader-Willi syndrome did not meet primary endpoint [Internet]. 2026 Aug [cited 2026 Sep 11]. Available from: https:\/\/acadia.com\/en-us\/media\/news-releases\/acadia-pharmaceuticals-announces-phase-3-compass-pws-trial."},{"key":"4601_CR63","unstructured":"Clinicaltrials.gov. ARD-101 for treatment of PWS: The Hunger Elimination or Reduction Objective Trial (HERO). Available at: https:\/\/clinicaltrials.gov\/study\/NCT06828861. Accessed January 2026."},{"key":"4601_CR64","doi-asserted-by":"publisher","unstructured":"Ferraz Barbosa B, Aquino de Moraes FC, Bordignon Barbosa C, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, for obese patients: a systematic review and meta-analysis. J Pers Med. 2023;4(10). https:\/\/doi.org\/10.3390\/jpm13101460.","DOI":"10.3390\/jpm13101460"},{"key":"4601_CR65","unstructured":"Aardvark Therapeutics. Aardvark Therapeutics announces voluntary pause of Phase 3 HERO trial in Prader-Willi syndrome. https:\/\/ir.aardvarktherapeutics.com\/news-releases\/news-release-details\/aardvark-therapeutics-announces-voluntary-pause-phase-3-hero."},{"issue":"7","key":"4601_CR66","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1210\/clinem\/dgad014","volume":"16","author":"JL Miller","year":"2023","unstructured":"Miller JL, Gevers E, Bridges N, et al. Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: A double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2023;108(7):1676\u201385. https:\/\/doi.org\/10.1210\/clinem\/dgad014.","journal-title":"J Clin Endocrinol Metab Jun"},{"key":"4601_CR67","doi-asserted-by":"publisher","unstructured":"Miller JL, Bridges N, Felner EI, et al. Diazoxide choline extended-release tablets in Prader-Willi syndrome: a randomized, double-blind, withdrawal period study. J Clin Endocrinol Metab. 2026;111(6):e1554\u2013e1561. https:\/\/doi.org\/10.1210\/clinem\/dgaf661.","DOI":"10.1210\/clinem\/dgaf661"},{"issue":"1","key":"4601_CR68","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s11689-024-09536-x","volume":"26","author":"TV Strong","year":"2024","unstructured":"Strong TV, Miller JL, McCandless SE, et al. Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study. J Neurodev Disord Apr. 2024;26(1):22. https:\/\/doi.org\/10.1186\/s11689-024-09536-x.","journal-title":"J Neurodev Disord Apr"},{"issue":"Suppl 1","key":"4601_CR69","first-page":"4","volume":"97","author":"E Gevers","year":"2024","unstructured":"Gevers E, Bridges JFP, Yanovski JA, et al. Long-term efficacy results of diazoxide choline extended-release (DCCR) tablets in participants with Prader-Willi syndrome from the completed C601 (DESTINY PWS) and C602 open label extension (OLE) studies. Horm Res Paediatr. 2024;97(Suppl 1):4\u2013295.","journal-title":"Horm Res Paediatr"},{"key":"4601_CR70","unstructured":"Rhythm Pharmaceuticals. Rhythm Pharmaceuticals Announces preliminary data from exploratory phase 2 trial that showed setmelanotide demonstrated positive efficacy signal in Prader-Willi syndrome. Available at: https:\/\/ir.rhythmtx.com\/news-releases\/news-release-details\/rhythm-pharmaceuticals-announces-preliminary-data-exploratory. Accessed March 2026."},{"issue":"9","key":"4601_CR71","doi-asserted-by":"publisher","first-page":"e0221615","DOI":"10.1371\/journal.pone.0221615","volume":"14","author":"V Kimonis","year":"2019","unstructured":"Kimonis V, Surampalli A, Wencel M, Gold JA, Cowen NM. A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome. PLoS ONE. 2019;14(9):e0221615. https:\/\/doi.org\/10.1371\/journal.pone.0221615.","journal-title":"PLoS ONE"},{"key":"4601_CR72","unstructured":"US Food and Drug Administration (FDA). FDA approves treatment for weight management in patients with Bardet-Biedl Syndrome aged 6 or older. Available at: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-weight-management-patients-bardet-biedl-syndrome-aged-6-or-older#:~:text=The%20U.S.%20Food%20and%20Drug,Effectiveness. Accessed March 2026."},{"issue":"4","key":"4601_CR73","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.2337\/dc13-2575","volume":"37","author":"D Fintini","year":"2014","unstructured":"Fintini D, Grugni G, Brufani C, Bocchini S, Cappa M, Crin\u00f2 A. Use of GLP-1 receptor agonists in Prader-Willi Syndrome: report of six cases. Diabetes Care Apr. 2014;37(4):e76\u20137. https:\/\/doi.org\/10.2337\/dc13-2575.","journal-title":"Diabetes Care Apr"},{"issue":"8","key":"4601_CR74","doi-asserted-by":"publisher","first-page":"E1314","DOI":"10.1210\/jc.2011-0038","volume":"96","author":"L Sze","year":"2011","unstructured":"Sze L, Purtell L, Jenkins A, et al. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J Clin Endocrinol Metab Aug. 2011;96(8):E1314\u20139. https:\/\/doi.org\/10.1210\/jc.2011-0038.","journal-title":"J Clin Endocrinol Metab Aug"},{"issue":"3","key":"4601_CR75","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/ijpo.12131","volume":"12","author":"P Salehi","year":"2017","unstructured":"Salehi P, Hsu I, Azen CG, Mittelman SD, Geffner ME, Jeandron D. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome. Pediatr Obes Jun. 2017;12(3):221\u20138. https:\/\/doi.org\/10.1111\/ijpo.12131.","journal-title":"Pediatr Obes Jun"},{"issue":"1","key":"4601_CR76","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1210\/clinem\/dgac549","volume":"17","author":"G Diene","year":"2022","unstructured":"Diene G, Angulo M, Hale PM, et al. Liraglutide for weight management in children and adolescents with Prader-Willi syndrome and obesity. J Clin Endocrinol Metab 2023;108(1):4\u201312. https:\/\/doi.org\/10.1210\/clinem\/dgac549.","journal-title":"J Clin Endocrinol Metab Dec"},{"issue":"1","key":"4601_CR77","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.diabres.2010.12.009","volume":"92","author":"IW Seetho","year":"2011","unstructured":"Seetho IW, Jones G, Thomson GA, Fernando DJ. Treating diabetes mellitus in Prader-Willi syndrome with Exenatide. Diabetes Res Clin Pract Apr. 2011;92(1):e1\u20132. https:\/\/doi.org\/10.1016\/j.diabres.2010.12.009.","journal-title":"Diabetes Res Clin Pract Apr"},{"issue":"6","key":"4601_CR78","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/j.1464-5491.2011.03280.x","volume":"28","author":"K Cyganek","year":"2011","unstructured":"Cyganek K, Koblik T, Kozek E, Wojcik M, Starzyk J, Malecki MT. Liraglutide therapy in Prader-Willi syndrome. Diabet Med Jun. 2011;28(6):755\u20136. https:\/\/doi.org\/10.1111\/j.1464-5491.2011.03280.x.","journal-title":"Diabet Med Jun"},{"issue":"10","key":"4601_CR79","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1507\/endocrj.ej12-0074","volume":"59","author":"M Senda","year":"2012","unstructured":"Senda M, Ogawa S, Nako K, Okamura M, Sakamoto T, Ito S. The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome. Endocr J. 2012;59(10):889\u201394. https:\/\/doi.org\/10.1507\/endocrj.ej12-0074.","journal-title":"Endocr J"},{"issue":"7","key":"4601_CR80","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1515\/jpem-2019-0389","volume":"28","author":"T Candler","year":"2020","unstructured":"Candler T, McGregor D, Narayan K, Moudiotis C, Burren CP. Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a case report. J Pediatr Endocrinol Metab Jul. 2020;28(7):951\u20135. https:\/\/doi.org\/10.1515\/jpem-2019-0389.","journal-title":"J Pediatr Endocrinol Metab Jul"},{"issue":"1","key":"4601_CR81","doi-asserted-by":"publisher","first-page":"52","DOI":"10.6065\/apem.2020.25.1.52","volume":"25","author":"YM Kim","year":"2020","unstructured":"Kim YM, Lee YJ, Kim SY, Cheon CK, Lim HH. Successful rapid weight reduction and the use of liraglutide for morbid obesity in adolescent Prader-Willi syndrome. Ann Pediatr Endocrinol Metab Mar. 2020;25(1):52\u20136. https:\/\/doi.org\/10.6065\/apem.2020.25.1.52.","journal-title":"Ann Pediatr Endocrinol Metab Mar"},{"key":"4601_CR82","doi-asserted-by":"publisher","unstructured":"Goldman VE, Naguib MN, Vidmar AP. Anti-obesity medication use in children and adolescents with Prader-Willi syndrome: case review and literature search. J Clin Med. 2021;30(19). https:\/\/doi.org\/10.3390\/jcm10194540.","DOI":"10.3390\/jcm10194540"},{"issue":"2","key":"4601_CR83","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/cen.14583","volume":"96","author":"NBH Ng","year":"2022","unstructured":"Ng NBH, Low YW, Rajgor DD, et al. The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review. Clin Endocrinol (Oxf) Feb. 2022;96(2):144\u201354. https:\/\/doi.org\/10.1111\/cen.14583.","journal-title":"Clin Endocrinol (Oxf) Feb"},{"issue":"2","key":"4601_CR84","doi-asserted-by":"publisher","first-page":"e35102","DOI":"10.7759\/cureus.35102","volume":"15","author":"S Ahmed","year":"2023","unstructured":"Ahmed S, Naz A. Weight Loss of Over 100 lbs in a Patient of Prader-Willi Syndrome Treated With Glucagon-Like Peptide-1 (GLP-1) Agonists. Cureus Feb. 2023;15(2):e35102. https:\/\/doi.org\/10.7759\/cureus.35102.","journal-title":"Cureus Feb"},{"issue":"10","key":"4601_CR85","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2174\/1871530322666220509225637","volume":"22","author":"E Sani","year":"2022","unstructured":"Sani E, Prato GD, Zenti MG, Bordugo A, Trombetta M, Bonora E. Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report. Endocr Metab Immune Disord Drug Targets. 2022;22(10):1053\u20137. https:\/\/doi.org\/10.2174\/1871530322666220509225637.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"4601_CR86","doi-asserted-by":"publisher","first-page":"1533209","DOI":"10.3389\/fendo.2025.1533209","volume":"16","author":"E Dinoi","year":"2025","unstructured":"Dinoi E, Daniele G, Michelucci A, et al. Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report. Front Endocrinol (Lausanne). 2025;16:1533209. https:\/\/doi.org\/10.3389\/fendo.2025.1533209.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4601_CR87","doi-asserted-by":"publisher","unstructured":"Gimenez-Palop O, Romero A, Casamitjana L, Pareja R, Rigla M, Caixas A. Effect of semaglutide on weight loss and glycaemic control in patients with Prader-Willi syndrome and type 2 diabetes. Endocrinol Diabetes Nutr. 2024;71(2):83\u20137. https:\/\/doi.org\/10.1016\/j.endien.2023.12.001.","DOI":"10.1016\/j.endien.2023.12.001"},{"key":"4601_CR88","doi-asserted-by":"publisher","first-page":"1528457","DOI":"10.3389\/fendo.2024.1528457","volume":"15","author":"A Koceva","year":"2024","unstructured":"Koceva A, Mlekus Kozamernik K, Janez A, Herman R, Ferjan S, Jensterle M. Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review. Front Endocrinol (Lausanne). 2024;15:1528457. https:\/\/doi.org\/10.3389\/fendo.2024.1528457.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4601_CR89","unstructured":"International Prader-Willi Syndrome Organisation (IPWSO). Is there a role for GLP-1 receptor agonists in Prader-Willi syndrome? Clinical and Scientific Advisory Board statement [Internet]. 2025 [cited 2026 Aug 27]. Available from: https:\/\/ipwso.org\/wp-content\/uploads\/2025\/02\/GLP-1-statement.pdf."},{"key":"4601_CR90","unstructured":"Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals plans to initiate Prader-Willi syndrome Phase 2 study of TNX-2900 [Internet]. 2026 Aug [cited 2026 Sep 11]. Available from: https:\/\/ir.tonixpharma.com."},{"key":"4601_CR91","unstructured":"Aardvark Therapeutics. Aardvark Therapeutics reports positive phase ii clinical data for ARD-101. Available at: https:\/\/ir.aardvarktherapeutics.com\/news-releases\/news-release-details\/aardvark-therapeutics-reports-positive-phase-ii-clinical-data?utm_source=chatgpt.com. Accessed January 2026."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04601-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04601-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04601-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:03:45Z","timestamp":1791245025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04601-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4601"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04601-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"10 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.T. has been a member of medical advisory board and a Chief Investigator on clinical trials for Millendo Therapeutics and Novo Nordisk; Principal Investigator for clinical trials on Oxytocin treatment in PWS, Head of the scientific advisory board of OT4B, Member of the scientific board for Soleno Therapeutics, a Neurocrine Biosciences company, to organise the Toulouse meeting on hyperphagia. J.M. has received research funding from: Soleno Therapeutics, a Neurocrine Biosciences company, Rhythm Pharmaceuticals, Harmony Biosciences, and Aardvark Therapeutics. AH is a consultant for Palobiofarma and has been a clinical investigator for a clinical trial sponsored by Soleno Therapeutics, a Neurocrine Biosciences company, and Harmony Biosciences. Research in PWS at the University of Cambridge has received a grant from Aardvark Therapeutics. G.D. is a member of the scientific board for Soleno Therapeutics, a Neurocrine Biosciences company to organise the Toulouse meeting on hyperphagia and is\/has been an investigator in clinical trials sponsored by Rhythm Pharmaceuticals, Harmony, Acadia, OBT4B and Novo Nordisk. C.P. is\/has been an investigator in clinical trials sponsored by Rhythm Pharmaceuticals and Novo Nordisk, and has received consulting\/advisory board fees from Soleno Therapeutics, a Neurocrine Biosciences company, and Rhythm Pharmaceuticals. C.H. is\/has been an Principal National Investigator for a clinical trial for Harmony Biosciences (PWS) and Debiopharm (acromegaly); received speaker honorarium fee from Soleno Therapeutics, a Neurocrine Biosciences company. E.G. is a principal investigator for Soleno Therapeutics, a Neurocrine Biosciences company, Aardvark Therapeutics, Acadia. Consulting and lecturing fees for Soleno Therapeutics, a Neurocrine Biosciences company, and Radius Health. Clinical fellow support from Soleno Therapeutics, a Neurocrine Biosciences company. A.P.G. is a consultant for Rhythm Pharmaceuticals and Novo Nordisk; has been a clinical investigator for clinical trials sponsored by Rhythm Pharmaceuticals, Millendo Therapeutics and Soleno Therapeutics, a Neurocrine Biosciences company; has been a consultant for Eli Lilly, Evidera, Helsinn Healthcare S.A, Idera Pharmaceuticals, Radius Health, Soleno Therapeutics, a Neurocrine Biosciences company, Tonix Pharmaceuticals and Vida Ventures; has been on Advisory Boards for Radius Health and Millendo Therapeutics; has been on Data Safety Monitoring Committee for Novo Nordisk; has received speaker fees from Eli Lilly, Novo Nordisk, Soleno Therapeutics, a Neurocrine Biosciences company, and Rhythm Pharmaceuticals, and research support from Novo Nordisk. A.M.H. served on an advisory board for Rhythm Pharmaceuticals, Inc., Pfizer, and is a principal investigator for clinical trials with Rhythm Pharmaceuticals, Inc., Acadia Pharmaceuticals, Eli Lilly, Novo Nordisk, and Aardvark Therapeutics. Y.H.C. is\/has been an Principal investigator for clinical trials sponsored by Harmony Biosciences and Aardvark Therapeutics, consultant for Soleno Therapeutics, a Neurocrine Biosciences company.A.H.S. has served as an investigator for Soleno Therapeutics, a Neurocrine Biosciences company, Aardvark Therapeutics, Novo Nordisk and Rhythm Pharmaceuticals. She has served as a consultant for Soleno Therapeutics, a Neurocrine Biosciences company, and is now an employee at Rhythm Pharmaceuticals. A.C. is\/has been consulting\/Advisory board and principal investigator for clinical trials sponsored by Palobiofarma SL and fees for talks from Soleno Therapeutics, a Neurocrine Biosciences company, and Rhythm Pharmaceuticals.E.G.B. has received speaker fees from Soleno Therapeutics, a Neurocrine Biosciences company, and research support from Soleno Therapeutics, a Neurocrine Biosciences company, and Pfizer. J.F., S.B., L.D.G., A.M., declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"347"}}